Jeffrey D. Chulay
Keine laufenden Positionen mehr
Profil
Jeffrey D.
Chulay served as the Chairman of the Department of Immunology at Walter Reed Army Institute of Research.
He also worked as a Principal at GSK Plc and as the Chief Medical Officer & Senior Vice President at AlphaVax, Inc. In 2015-2016, he was the Chief Medical Officer & Vice President at Beacon Therapeutics (USA), Inc. Chulay received his undergraduate degree from the London School of Hygiene & Tropical Medicine and his doctorate from the Feinberg School of Medicine.
Ehemalige bekannte Positionen von Jeffrey D. Chulay
| Unternehmen | Position | Ende |
|---|---|---|
| Walter Reed Army Institute of Research | Corporate Officer/Principal | - |
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Technik-/Wissenschafts-/F&E-Leiter | - |
| GSK PLC | Corporate Officer/Principal | - |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2016 |
Ausbildung von Jeffrey D. Chulay
| Feinberg School of Medicine | Doctorate Degree |
| London School of Hygiene & Tropical Medicine | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
| Walter Reed Army Institute of Research |
